Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Markers Identified for Early Onset Prostate Cancer Risk

By LabMedica International staff writers
Posted on 17 Jun 2010
Single nucleotide polymorphisms (SNPs) associated with prostate cancer risk has been confirmed in younger men with aggressive forms of the disease. More...
A single-nucleotide polymorphism is a DNA sequence variation occurring when a single nucleotide in the genome differs between individuals.

Genetics and traditional screening methods could play a role in predicting the risk of prostate cancer in younger men. Early diagnosis and therefore early treatment is more feasible when the Prostate Screening Antigen (PSA) test is combined with specific gene screening,

In a study, carried out by scientists at the University of Michigan Comprehensive Cancer Center (U-M, Ann Arbor, MI, USA), 14 genetic mutations were looked for in 754 men aged 56 or younger with prostate cancer. The screening results from this group were compared with those from 1,163 prostate cancer patients over the age of 56 and 2,713 men without prostate cancer.

The younger men diagnosed with early onset prostate cancer had a greater frequency of risk alleles that either of the other two groups. In addition, 30% of the younger men had aggressive prostate cancer and 41% of these men had at least one first-degree relative with prostate cancer.

Professor Kathleen Cooney, M.D, the lead scientist in this study, said, "Early onset prostate cancer has a strong genetic component, which we saw in this study. Our next step is to look more widely for novel genetic variants among this group of men."

They will next look at the genome of a larger population of men with early onset prostate cancer to find common mutations that may be linked to the disease. The results of the study were presented in June 2010 at the American Society of Clinical Oncology annual meeting,

Prostate cancer is the most common neoplasm amongst men of all races in the U.S., and around 200,000 new cases occur annually and about 28,000 will die from the disease. In the U.K., the incidence rate is 120.7/100,000 and even higher in most western European countries. The risk of prostate cancer increases with age, consequently early diagnosis and treatment can save lives.

Related Links:

University of Michigan
American Society of Clinical Oncology




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.